Nov 4, 2025 07:02AM GENPREX receives European patent intent for cancer gene therapy combination

Oct 28, 2025 07:00AM GENPREX collaborators present preclinical data for lung cancer therapy

Oct 23, 2025 07:02AM Genprex collaborators to present lung cancer gene therapy data at conference

Sep 12, 2025 04:48PM Genprex (GNPX) files for 25M share offering by selling stockholders

Aug 4, 2025 08:31AM Genprex issues stockholder letter with 2025 corporate update

Jun 24, 2025 09:25AM Genprex (GNPX) Collaborators Present Positive Preclinical Research on Diabetes Gene Therapy

Apr 28, 2025 07:30AM Genprex (GNPX) Signs Exclusive Technology License Agreement with New York University Langone Health for the Treatment of Mesothelioma

Apr 22, 2025 08:15AM Genprex (GNPX) Announces Research Collaborators' Abstract Published in Cancer Research Supplement Proceedings

Mar 26, 2025 08:16AM Genprex (GNPX) Collaborators to Present Positive Preclinical Data on the Use of Reqorsa Gene Therapy

Feb 19, 2025 08:16AM Genprex (GNPX) Advances Diabetes Program with Addition of Research Focused on Non-Viral Delivery System

Feb 18, 2025 08:16AM Genprex (GNPX) Provides Update on Diabetes Gene Therapy Program

Dec 16, 2024 09:15AM Genprex (GNPX) Receives Safety Review Committee Approval to Advance to Phase 2 Portion of Acclaim-3 Clinical Trial of Reqorsa® Gene Therapy in Combination with Tecentriq in Extensive Stage Small Cel

Nov 20, 2024 09:29AM Genprex (GNPX) Signs Exclusive License to Additional Gene Therapy Technologies with the University of Michigan for the Treatment of Lung Cancer

Nov 5, 2024 09:30AM Genprex (GNPX) Collaborators Present Positive Preclinical Data on Reqorsa Gene Therapy

Oct 28, 2024 09:30AM Genprex (GNPX) Collaborators Present Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Lung Cancer, Mesothelioma and Glioblastoma

Oct 24, 2024 09:30AM Genprex (GNPX) Announces Sponsored Research Agreement with The University of Michigan Rogel Cancer Center and Lung Cancer Study Collaboration with ALK Positive

Oct 15, 2024 09:29AM Genprex (GNPX) Receives Safety Review Committee Approval to Advance to Highest Dose Group in Phase 1 Portion of Acclaim-3 Clinical Trial of Reqorsa® Gene Therapy in Combination with Tecentriq® in Ex

Sep 19, 2024 09:29AM Genprex (GNPX) Forms Mesothelioma Clinical Advisory Board

Sep 4, 2024 09:29AM Genprex (GNPX) to Launch Separate Company to Focus on the Development of Gene Therapy to Treat Type-1 and Type-2 Diabetes

Aug 14, 2024 09:25AM Genprex (GNPX) Reports Positive Clinical Study Updates from Acclaim-1 and Acclaim-3 Phase 1/2 Trials

Aug 13, 2024 08:31AM Genprex (GNPX) Granted Patent in Singapore for Reqorsa Gene Therapy